welcome
Investor's Business Daily

Investor's Business Daily

Health

Health

Arcutis Biotherapeutics (ARQT) stock soars on hopes to eliminate eczema and psoriasis trade-off

Investor's Business Daily
Summary
Nutrition label

50% Informative

Arcutis Biotherapeutics (ARQT) wants to eliminate a terrible trade-off for patients with eczema and psoriasis.

Topical steroids are a mainstay in treating itchy skin conditions.

But they come with a host of side effects, including skin thinning and spider veins.

VR Score

38

Informative language

37

Neutral language

12

Article tone

formal

Language

English

Language complexity

56

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.